Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a MALT1 blocker tame Hard-to-Treat lymphoma?

NCT ID NCT06622226

Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called ONO-7018 in people with relapsed or refractory Non-Hodgkin lymphoma. The drug works by blocking a protein called MALT1 that may help lymphoma cells grow. The study aims to see if the drug is safe and tolerable, and how it behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ONO-7018, a MALT1 inhibitor tablet taken by mouth
What this could lead to
If successful, this could lead to a new treatment option for people with Non-Hodgkin lymphoma that has not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 2 participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

2 people

The number who actually took part.

Started

Nov 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with histologically/cytologically confirmed diagnosis of any of the subtypes of B-cell NHL or T-cell NHL defined below as documented by medical records and with histology based on criteria established by the World Health Organization (Swerdlow 2017) 2. Relapsed or refractory patient who is refractory or intolerant to standard therapy or for whom, in the opinion of the investigator, there is no appropriate treatment for the primary disease. 3. Patient who has measurable disease 4. Eastern Cooperative Oncology Group Performance Status 0 to 2 5. Life expectancy of at least 3 months Exclusion Criteria: 1. Any serious or uncontrolled medical disorder that may increase the risk associated with study participation or study treatment, or interfere with the interpretation of study results 2. Patient with malignancies other than lymphoid malignancy allowed per inclusion criteria 3. Prior treatment with a MALT1 inhibitor 4. Patient is unable to swallow tablets

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-Hodgkin lymphoma

Contacts and locations

Locations

  • Hiroshima Red Cross Hospital Atomic-bomb Survivors Hospital

    Hiroshima, Hiroshima, Japan

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, Osaka, Japan

  • National Hospital Organization Sendai Medical Center

    Sendai, Miyagi, Japan

  • National Hospital Organization Shibukawa Medical Center

    Shibukawa-shi, Gunma, Japan

  • The Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.